Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Actin, aortic smooth muscle (encoded by the ACTA2 gene) is a highly conserved cytoskeletal protein that belongs to the actin family and serves as a major component of the contractile apparatus in vascular smooth muscle cells (VSMCs). It plays a critical role in maintaining vascular tone, blood pressure homeostasis, and the structural integrity of blood vessels. Beyond its physiological role in smooth muscle contraction, ACTA2 is a well-established marker of myofibroblast differentiation and is highly expressed in activated cancer-associated fibroblasts (CAFs), where it contributes to stromal remodeling, tissue fibrosis, and tumor progression. Mutations in the ACTA2 gene, such as the severe R179H variant, disrupt actin filament assembly and lead to life-threatening conditions like familial thoracic aortic aneurysm and dissection (TAAD), early-onset stroke, Moyamoya disease, and multisystemic smooth muscle dysfunction syndrome (SMDS).
Therapeutically, ACTA2 is targeted through novel genetic approaches, including bespoke CRISPR-Cas9 base editors and lipid nanoparticle (LNP) or adeno-associated virus (AAV) gene therapies designed to correct pathogenic mutations directly within the vasculature. Additionally, repurposed metabolic therapies like sapropterin and nicotinamide riboside are being evaluated to improve smooth muscle cell function and reduce vascular complications. In oncology, ACTA2 serves as a key biomarker for predicting resistance to therapies like trastuzumab and monitoring glioma recurrence, making it a high-value target for both diagnostic and therapeutic interventions.
Direct genomic correction of pathogenic ACTA2 variants using CRISPR-Cas9 base editors or gene therapy; metabolic support and improvement of smooth muscle cell function via sapropterin or nicotinamide riboside; downregulation of expression using siRNA/miRNA; downstream inhibition of contractility and stress fiber formation via ROCK inhibitors.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Actin, aortic smooth muscle (ACTA2).